DIVI S LABORATORIES LTD vs SOTAC PHARMACEUTICALS LTD

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and SOTAC PHARMACEUTICALS LTD (SOTAC) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs SOTAC on 11 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

74.93
P/E ratio
18.22
10.72
P/B ratio
1.89
0.44%
Dividend yield
0.10%
₹96.73
EPS
₹5.22

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
10.30%
22.00%
Return on capital
13.00%
33.00%
EBITDA margin
18.00%
24.32%
Net margin
5.94%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
9.47%
12.10%
Profit CAGR (3Y)
44.22%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.92L Cr
Market cap
₹0 Cr
₹10,560 Cr
Revenue
₹101 Cr
₹2,568 Cr
Net profit
₹6 Cr
0.00
Debt / equity
0.64
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 10.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
SOTAC PHARMACEUTICALS LTD
  • + ["Company has delivered good profit growth of 34.7% CAGR over last 5 years"]
  • ["Company has a low return on equity of 13.0% over last 3 years."]
DIVI S LABORATORIES LTD full analysis SOTAC PHARMACEUTICALS LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

DIVI S LABORATORIES LTD vs SOTAC PHARMACEUTICALS LTD: Share Price, Valuation & Which to Buy | DocStoX